Search peptides, terms, sources/
Growth hormone axis

GHRP-6

Also known as: Growth hormone-releasing peptide-6

Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. 1 further finding at this grade tested a combination with another substance, not GHRP-6 alone, and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHRP-6 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials3 human trials of GHRP-6 alone · 1 combination trial (with GHRH) · 2 animal studies

What is GHRP-6?

GHRP-6 is a synthetic six-amino-acid peptide that stimulates the pituitary gland to release growth hormone. It is not licensed in the UK, and the human research is short hormone-response, pharmacokinetic and diagnostic-test work, with no trial showing a health benefit.

Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does GHRP-6 work?

GHRP-6 is understood to work through the growth hormone secretagogue receptor, the system the body's own hormone ghrelin uses, although the foundational receptor study did not test GHRP-6 itself. In a human experiment, most of its effect needed the body's own GHRH, and it also released ACTH and cortisol. A large growth hormone response is a measurement, not evidence of any health benefit.

The mechanism in more detail

GHRP-6 belongs to the growth hormone-releasing peptides, a class of synthetic growth hormone secretagogues. Synthetic secretagogues were known to release growth hormone through a receptor before the body’s own ligand, ghrelin, was isolated in 1999. GHRP-6 is understood to work through that same system, although the foundational receptor study did not test GHRP-6 itself.

In a human experiment, blocking the body’s own growth-hormone-releasing hormone (GHRH) cut the response to GHRP-6 sharply, so most of its effect depends on GHRH already being present. GHRP-6 also releases ACTH and cortisol, so it is not a selective growth hormone stimulant.

The strong growth hormone response to GHRP-6 together with GHRH is the basis for its study as a diagnostic stimulus in adults with suspected growth hormone deficiency. A large growth hormone response is a physiological measurement. It is not evidence of any health benefit, and no human trial testing a health outcome was identified.

Classification and structure

Names
GHRP-6; Growth hormone-releasing peptide-6
Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
Structure
Synthetic hexapeptide (six amino acids), molecular weight about 872.
Routes used in the research
Intravenous injection in the cited human studies where the route is stated. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

GHRP-6 has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
24000

1 of the findings graded Limited tested a combination with another substance, not GHRP-6 alone, so it is not counted in the evidence grade at the top of the page.

GHRH plus GHRP-6 diagnostic test Limited Combination, not GHRP-6 alone

In a multicentre study of 125 adults with pituitary disease and 125 healthy controls, a test using GHRH together with GHRP-6 produced far larger growth hormone peaks in controls (average about 59 micrograms per litre) than in patients (about 4), a wider gap than the insulin tolerance test showed (about 14 versus 0.5). The authors proposed a cut-off for deficiency and reported no side effects during testing. This supports using the combination as a diagnostic stimulus. It is not a test of treatment.

Study type
Human trial
Population
Human adults: 125 with organic pituitary disease and 125 healthy controls, multicentre
Source
1 Popovic et al., 2000

Limitation: GHRP-6 was tested together with GHRH, not on its own.

Limitations in full

GHRP-6 was tested together with GHRH, not on its own. The abstract gives no sensitivity or specificity figures. It tests a diagnostic use, not any treatment effect.

Phase I pharmacokinetics, nine men Limited

In nine healthy men given a single intravenous injection at three different amounts, GHRP-6 left the blood in two phases: a distribution half-life of about 7.6 minutes and an elimination half-life of about 2.5 hours. Exposure rose roughly in step with the amount given. The authors noted unexpected concentration spikes during elimination in four of the nine men.

Study type
Human trial
Population
Human healthy adult men, 9 participants, Phase I
Source
2 Cabrales et al., 2013

Limitation: Nine men.

Limitations in full

Nine men. It measures how fast the peptide leaves the blood, not any effect on health.

Depends on the body's own GHRH Limited

In nine healthy men aged 20 to 30, blocking the body's own growth-hormone-releasing hormone with an antagonist cut the growth hormone response to GHRP-6 sharply: the peak rise fell from about 34 to about 6 micrograms per litre. The authors conclude that most of the response to GHRP-6 in humans needs endogenous GHRH.

Study type
Human trial
Population
Human healthy men aged 20 to 30, 9 participants, randomised crossover
Source
3 Pandya et al., 1998

Limitation: Nine young men; a mechanism study of a hormone response, not a health outcome.

ACTH and cortisol release Limited

In 20 patients with an overactive thyroid and 9 controls, ghrelin and GHRP-6 each triggered ACTH and cortisol release over 90 minutes. Cortisol responses to GHRP-6 were similar in both groups. The ACTH response to GHRP-6 was higher in the patients, but the difference was not statistically significant.

Study type
Human trial
Population
Human: 20 patients with thyrotoxicosis and 9 controls
Source
4 Pituitary, 2009

Limitation: Small, 90-minute hormone-response study in a specific patient group.

Limitations in full

Small, 90-minute hormone-response study in a specific patient group. It was not designed to test safety or benefit.

Rat heart-attack model, 2026 Preliminary

In rats with a surgically induced heart attack, a week of GHRP-6 treatment was reported to reduce tissue death and scarring in the heart muscle and to improve pumping function. Protein analysis in healthy rats suggested changes in fat-burning, anti-cell-death and antioxidant pathways. This is rat work only.

Study type
Animal
Population
Rats with surgically induced myocardial infarction; healthy rats for protein analysis
Source
5 Wang et al., 2026

Limitation: Rat study, group sizes not given in the abstract.

Limitations in full

Rat study, group sizes not given in the abstract. Several authors also appear on the 2013 human pharmacokinetic paper cited here, and the record lists no conflict-of-interest statement.

Receptor background (class level) Preliminary

Synthetic growth hormone secretagogues were known to release growth hormone through a receptor (GHS-R) before its natural partner was found. In 1999 researchers isolated ghrelin from rat stomach as that partner and showed it releases growth hormone in living animals and in cell experiments. This underlies the understanding that GHRP-6 works through the same system. The study did not test GHRP-6 itself.

Study type
Animal
Population
Rat tissue and rats; no human participants
Source
6 Kojima et al., 1999

Limitation: Class-level background only.

Limitations in full

Class-level background only. GHRP-6 was not tested in this study.

What safety findings have been reported?

2 safety findings are recorded for GHRP-6. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Releases ACTH and cortisol

GHRP-6 provoked ACTH and cortisol release in both patients with an overactive thyroid and controls over 90 minutes. This is a hormone effect worth knowing about. The study was not designed to measure harm.

Source
4 Pituitary, 2009

Insulin and glucose rise in an artificial set-up

In healthy men who had eaten and whose growth hormone receptor had been blocked by another drug, GHRP-6 caused a sharp acute rise in insulin and blood glucose in a subgroup of five. This did not happen during fasting or without the blocker. The authors described it as tissue-specific insulin resistance and noted the study was acute, so longer-term results could differ. It is an artificial set-up and does not describe normal use.

Source
7 Muller et al., 2001

What is GHRP-6's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for GHRP-6.
Prescription status
Not applicable, no licensed UK product was found to classify.
Medicine class
Not classified as a licensed medicine in the UK.
MHRA position
No GHRP-6-specific MHRA notice was identified in this review. The review did not include a systematic search of MHRA enforcement releases. Supplying an unlicensed product for human use as a medicine falls under the Human Medicines Regulations 2012.
Authorised use
None.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names GHRP-6 under S2.2.4, growth hormone secretagogues and growth hormone-releasing peptides.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHRP-6 is recorded as not licensed in the UK (checked 14 November 2026).

References

8 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF (2000). GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. The LancetHuman clinical trial · DOI 10.1016/s0140-6736(00)02755-0 · PMID 11030292 · Original ↗
  2. Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European Journal of Pharmaceutical SciencesHuman clinical trial · DOI 10.1016/j.ejps.2012.10.006 · PMID 23099431 · Original ↗
  3. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA (1998). Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology and MetabolismHuman clinical trial, RCT · DOI 10.1210/jcem.83.4.4711 · PMID 9543138 · Original ↗
  4. Nascif SO, Molica P, Correa-Silva SR, Silva MR, Lengyel AMJ (2009). Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis. PituitaryHuman clinical trial · DOI 10.1007/s11102-009-0181-3 · PMID 19396632 · Original ↗
  5. Wang L, Rodriguez-Ulloa A, Berlanga-Acosta J, García-Ojalvo A, Abreu-Cruz A, Gonzalez-López LJ, Besada-López V, Ramos-Gómez Y, Guillén-Nieto G, Jiang B (2026). Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. Pharmaceuticals (Basel)Animal-preclinical · DOI 10.3390/ph19030468 · PMID 41901314 · Original ↗
  6. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. NatureAnimal-preclinical, In-vitro · DOI 10.1038/45230 · PMID 10604470 · Original ↗
  7. Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ (2001). Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. Journal of Clinical Endocrinology and MetabolismHuman clinical trial, RCT · DOI 10.1210/jcem.86.2.7173 · PMID 11158013 · Original ↗
  8. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about GHRP-6

What is GHRP-6?

GHRP-6 is a synthetic six-amino-acid peptide that stimulates the pituitary gland to release growth hormone. It is not licensed in the UK, and the human research is short hormone-response, pharmacokinetic and diagnostic-test work, with no trial showing a health benefit. Read what it is.

Is GHRP-6 licensed in the UK?

PeptGuru records GHRP-6's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on GHRP-6 show?

PeptGuru records 6 research findings for GHRP-6: 4 from human trials and 2 from animal studies. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for GHRP-6?

2 safety findings are recorded, including: releases ACTH and cortisol; insulin and glucose rise in an artificial set-up. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for GHRP-6?

All 8 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · GHRP-6 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • IpamorelinIPA

    Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare GHRP-6 with GHRP-2

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.